Follow-Up Schedule for 16-Year-Old Starting Lexapro
A 16-year-old starting Lexapro should be seen in person within 1 week of initiation, then weekly for the first month, followed by visits at 6,8, and 12 weeks. 1
Initial Follow-Up (Week 1)
The GLAD-PC guidelines strongly recommend an in-person assessment within 1 week of starting any SSRI in adolescents 1. While telephone contact may be equally effective for monitoring adverse events based on research showing high reliability of phone interviews with adolescents, the expert consensus prioritizes face-to-face evaluation during this critical early period 1.
Intensive Monitoring Phase (Weeks 1-4)
Close monitoring during the first month is mandatory due to the FDA black-box warning for suicidal thinking and behavior in patients under age 24 2. The FDA explicitly states: "All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes" 1.
At Every Assessment, Evaluate:
- Ongoing depressive symptoms - Track symptom trajectory
- Suicide risk - Direct questioning about suicidal ideation or behavior
- Adverse effects - Use specific adverse-effect checklists including:
- Behavioral activation/agitation (motor restlessness, insomnia, impulsiveness, disinhibited behavior)
- Switch to mania/hypomania
- Physical side effects (nausea, headache, sleep changes)
- Treatment adherence - Confirm patient is taking medication as prescribed
- Environmental stressors - New or ongoing psychosocial factors 1
Continuation Phase (Weeks 6-12)
Continue regular monitoring at weeks 6,8, and 12, as the best-fitting model for SSRI response shows clinically significant improvement by week 6 and maximal improvement by week 12 or later 3. This schedule aligns with the critical period when relapse risk is highest (first 8-12 weeks after discontinuation) 1.
Critical Safety Considerations
Behavioral activation is more common in younger patients and typically occurs early in treatment or with dose increases 3. For your 16-year-old patient, start at 10 mg daily (not higher doses, which increase self-harm risk) 1, 2. If dose escalation is needed, wait at least 3 weeks between increases to the maximum 20 mg daily 2.
The pooled absolute risk for suicidal ideation with antidepressants is 1% versus 0.2% with placebo (number needed to harm = 143), but this small absolute risk necessitates vigilant monitoring 3.
Practical Implementation
Telephone or email contact can supplement but should not replace in-person visits during the first month 1. Research shows that only 55% of patients see a provider within the first 4 weeks of antidepressant initiation in usual care, and only 14.9% receive FDA-recommended follow-up levels 4. Don't fall into this common pitfall of inadequate monitoring.
Document all monitoring contacts explicitly, as 40% of adolescents prescribed antidepressants have no documented follow-up care for 3 months in real-world practice 5. This represents a significant quality-of-care gap that increases morbidity risk.
Dosing Specifics for This Patient
Start at 10 mg once daily 2. The FDA label specifies that for adolescents 12 years and older with depression, dose increases to 20 mg should occur at intervals of no less than 3 weeks 2. This slower titration schedule (compared to 1 week in adults) helps minimize behavioral activation risk and allows adequate time to assess response 1, 2.